Stryker has announced in a press release that its OptaBlate bone tumour ablation system (OptaBlate) has received 510(k) clearance from the US Food and Drug Administration (FDA). The addition of the OptaBlate technology to Stryker’s Interventional Spine (IVS) portfolio expands on its core competencies in vertebral augmentation and radiofrequency ablation and completes its portfolio of treatment options for metastatic vertebral body fractures.
“Stryker’s new bone tumour ablation (BTA) system is a significant improvement on existing technology and builds on Stryker’s IVS portfolio,” said Anthony Brown, a vascular and interventional radiologist at Radiology Imaging Associates (Englewood, USA).
As Stryker’s first interventional oncology technology, OptaBlate optimises all aspects of the procedure, from set-up to ablation. Featuring four probes and Stryker’s patented microinfusion technology, OptaBlate allows physicians to customise their procedure and reduce ablation time by three minutes.
Specific key features of the system include:
- Treatment of two vertebral body levels at once using a bipedicular approach
- Quicker, more consistent ablation
- Microinfusion technology, which keeps the zone hydrated, reducing impedance errors and preventing charring
“The collaboration has helped us to develop a more efficient bone tumour ablation system to address their unmet needs,” said Greg Siller, vice president and general manager, interventional spine business, Stryker. “OptaBlate will help our customers provide another treatment option for those suffering from painful metastatic cancer.”
